At UroGen, making the impossible possible for patients with urological cancers is a reality, not just an idea.
Location: United States, New Jersey, Princeton
Employees: 51-200
Total raised: $75M
Founded date: 2004
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.03.2021 | - | $75M | - |
Mentions in press and media 13
| Date | Title | Description |
| 12.01.2026 | Arkin Capital Closes $100 Million Bio Ventures III Fund For Early-Stage Biotech Investing | Arkin Capital announced it has closed Arkin Bio Ventures III, a $100 million fund that will back advanced pre-clinical and early clinical-stage biotechnology companies developing therapies for high unmet medical needs. The firm said the new... |
| 18.03.2021 | UroGen Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments | PRINCETON, N.J.--(BUSINESS WIRE)--Mar 18, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced fi... |
| 18.03.2021 | UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments | PRINCETON, N.J.--(BUSINESS WIRE)--Mar 18, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced th... |
| 15.03.2021 | UroGen Pharma Announces Sponsored Research Agreement with the Johns Hopkins University School of Medicine to Expand Immuno-Oncology Pipeline | PRINCETON, N.J.--(BUSINESS WIRE)--Mar 15, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced a ... |
| 11.03.2021 | UroGen Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 18, 2021 | PRINCETON, N.J.--(BUSINESS WIRE)--Mar 11, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced th... |
| 05.05.2017 | Term Sheet — Friday, May 5 | CRYPTO-SPLAINING Last week a very confusing press release crossed my radar. It read: “The Argon Group is working on the first secondary market raise by ICO. The company, Storj had one of the most successful ICOs several years ago, returning... |
| 04.05.2017 | Term Sheet — Thursday, May 4 | ET CETERA New money: Heap, an analytics software company, has raised $27 million in Series B funding led by NEA and Menlo Ventures with participation from Initialized Capital and Pear VC. Heap CEO and co-founder Matin Movassate created the ... |
| 25.04.2017 | Term Sheet — Tuesday, April 25 | MONEY-LOSING HOUSE OF HORRORS Contrarian: The message around Cloudera’s IPO, which is expected to price on Thursday after the market closes, has been yikes. The company was last valued at $4.1 billion; its share pricing values the company a... |
| - | The next frontier in bladder cancer treatment | The future landscape according to urologic oncology experts November is National Bladder Health Month and a time to reflect on UroGen’s journey to transform care for patients with urothelial cancers. Advances in the treatment of urothelial ... |
| - | UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | PRINCETON, N.J.--(BUSINESS WIRE)--Mar 5, 2021-- UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the ... |
Show more